Retinoblastoma tumorigenesis: Genetic and epigenetic changes walk hand in hand

Future Oncology

Volumn 8, Issue 5, 2012, Pages 525-528

  Temming, Petra ^a,b   Corson, Timothy W ^c   Lohmann, Dietmar R ^a  

^a Department of Human Genetics   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

BCOR; DNA methylation; epigenetic regulation; gene expression; histone modification; RB1; retinoblastoma; SYK; tumorigenesis; whole genome sequencing

Indexed keywords

BCOR GENE; CARCINOGENESIS; EPIGENETICS; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOME; GENOME ANALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RB1 GENE; RETINOBLASTOMA; REVIEW; SYK GENE; TUMOR GENE;

EID: 84861724937     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.41     Document Type: Review

References (17)

1. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res. 59(Suppl. 7), S1731-S1735 (1999).
2. Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012).
3. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578-2585 (2010).
4. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363(14), 1303-1312 (2010).
5. Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46(7), 617-634 (2007). (Pubitemid 46802329)
6. Dimaras H, Khetan V, Halliday W et al. Loss of RB1 induces non-proliferative retinoma: Increasing genomic instability correlates with progression to retinoblastoma. Hum. Mol. Genet. 17(10), 1363-1372 (2008). (Pubitemid 351627333)
7. Gratias S, Rieder H, Ullmann R et al. Allelic loss in a minimal region on chromosome 16q24 is associated with vitreous seeding of retinoblastoma. Cancer Res. 67(1), 408-416 (2007). (Pubitemid 46142800)
8. Herzog S, Lohmann DR, Buiting K et al. Marked differences in unilateral isolated retinoblastomas from young and older children studied by comparative genomic hybridization. Hum. Genet. 108(2), 98-104 (2001). (Pubitemid 32215367)
9. Grossmann V, Tiacci E, Holmes AB et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood 118(23), 6153-6163 (2011).
10. Ng D, Thakker N, Corcoran CM et al. Oculofaciocardiodental and Lenz microphthalmia syndromes result from distinct classes of mutations in BCOR. Nat. Genet. 36(4), 411-416 (2004). (Pubitemid 38437266)
11. Laurie NA, Donovan SL, Shih CS et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115), 61-66 (2006). (Pubitemid 44684754)
12. Merbs SL, Khan MA, Hackler L Jr et al. Cell-specific DNA methylation patterns of retina-specific genes. PloS ONE 7(3), e32602 (2012).
13. Baudot AD, Jeandel PY, Mouska X et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28(37), 3261-3273 (2009).
14. Gobessi S, Laurenti L, Longo PG et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23(4), 686-697 (2009).
15. Buchner M, Baer C, Prinz G et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115(22), 4497-4506 (2010).
16. Murphree AL, Triche TJ. An epigenomic mechanism in retinoblastoma: The end of the story? Genome Med. 4(2), 15 (2012).
17. Yamamoto N, Takeshita K, Shichijo M et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c] pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 306(3), 1174-1181 (2003). (Pubitemid 37025329)